Could a simpler malaria vaccine dose protect more kids?
NCT ID NCT07036159
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 38 times
Summary
This study is testing whether giving the RTS,S/AS01E malaria vaccine (Mosquirix) in lower doses or on different schedules is safe and triggers a strong immune response in healthy children aged 5 months to 5 years. The goal is to find simpler ways to vaccinate children in areas where malaria is common. Around 238 children will take part, and researchers will measure their antibody levels and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGKigali, Rwanda
-
GSK Investigational Site
RECRUITINGKigali, Rwanda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RTS,S/AS01E malaria vaccine (Mosquirix)
What this could lead to
If successful, this could show that simpler, lower-dose regimens of the malaria vaccine are safe and effective, making it easier and cheaper to protect more children.
What could go wrong
This is a small Phase 2a study (238 children) focused on safety and immune response, not on preventing malaria itself. Lower doses may not provide enough protection, and results may not apply to all settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.